Your browser doesn't support javascript.
loading
GADD45ß Loss Ablates Innate Immunosuppression in Cancer.
Verzella, Daniela; Bennett, Jason; Fischietti, Mariafausta; Thotakura, Anil K; Recordati, Camilla; Pasqualini, Fabio; Capece, Daria; Vecchiotti, Davide; D'Andrea, Daniel; Di Francesco, Barbara; De Maglie, Marcella; Begalli, Federica; Tornatore, Laura; Papa, Salvatore; Lawrence, Toby; Forbes, Stuart J; Sica, Antonio; Alesse, Edoardo; Zazzeroni, Francesca; Franzoso, Guido.
Afiliación
  • Verzella D; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Bennett J; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Fischietti M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Thotakura AK; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Recordati C; Mouse & Animal Pathology Laboratory, Fondazione Filarete, Milan, Italy.
  • Pasqualini F; Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Capece D; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Vecchiotti D; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • D'Andrea D; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Di Francesco B; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • De Maglie M; Mouse & Animal Pathology Laboratory, Fondazione Filarete, Milan, Italy.
  • Begalli F; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Tornatore L; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Papa S; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London, United Kingdom.
  • Lawrence T; Current address: Leeds Institute of Cancer and Pathology (LICAP), University of Leeds, Leeds, United Kingdom.
  • Forbes SJ; Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, Inserm, CNRS, Marseille, France.
  • Sica A; Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Alesse E; Department of Inflammation and Immunology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Zazzeroni F; Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', Novara, Italy.
  • Franzoso G; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Cancer Res ; 78(5): 1275-1292, 2018 03 01.
Article en En | MEDLINE | ID: mdl-29279355
ABSTRACT
T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45ß that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poor clinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45ß for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.

Significance:

These findings define a myeloid-based immune checkpoint that restricts T-cell trafficking into tumors, with potentially important therapeutic implications to generally improve the efficacy of cancer immunotherapy. Cancer Res; 78(5); 1275-92. ©2017 AACR.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Antígenos de Diferenciación / Terapia de Inmunosupresión / Carcinoma Hepatocelular / Microambiente Tumoral / Tolerancia Inmunológica / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Cancer Res Año: 2018 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Asunto principal: Antígenos de Diferenciación / Terapia de Inmunosupresión / Carcinoma Hepatocelular / Microambiente Tumoral / Tolerancia Inmunológica / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Cancer Res Año: 2018 Tipo del documento: Article País de afiliación: Italia